Never mind the patent cliff, 2011 was bumper year for new drugs
This article was originally published in Scrip
Executive Summary
While the unprecedented number of major drugs losing patent protection in 2011 and 2012 has cast a gloomy shadow, the industry has quietly had one of its best years for launching novel therapies.